BioVie, Inc. filings document a Nevada clinical-stage biopharmaceutical company with Nasdaq-listed Class A common stock and, in certain filings, warrants tied to its capital structure. Material-event reports cover securities offerings, underwriting agreements and issuances involving units, pre-funded units and warrants.
Proxy statements and related 8-K filings describe annual meeting voting matters, director elections, board appointments and amendments to the company’s omnibus equity incentive plan. Registration statement amendments provide formal disclosure for offering activity and financial-statement periods associated with BioVie’s development-stage operations.
BioVie held a Special Meeting of stockholders on June 23, 2025, with 10,971,031 shares represented out of 18,570,726 outstanding shares of Class A common stock. Two key proposals were voted on:
Proposal 1: Reverse Stock Split Authorization The stockholders approved granting the Board authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-10, to be executed within one year. The voting results showed:
- For: 8,664,435 shares (79%)
- Against: 2,200,874 shares
- Abstain: 105,722 shares
Proposal 2: Meeting Adjournment Authority Shareholders approved discretionary authority to adjourn the meeting if needed to gather more proxies, with:
- For: 8,788,143 shares (80%)
- Against: 2,033,834 shares
- Abstain: 149,054 shares